Skip to main content
CRDF
NASDAQ Life Sciences

Cardiff Oncology Reports Short Cash Runway, Advances Lead Drug to Phase 3 with FDA Alignment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.73
Mkt Cap
$118.271M
52W Low
$1.48
52W High
$4.555
52W Position info
17% above low
Off High info
62% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

CRDF sits 17% above its 52-week low of $1.48.

Summary

Cardiff Oncology reported Q1 2026 results, revealing a short cash runway into Q1 2027, but also announced significant clinical progress with FDA alignment for a Phase 3 trial of its lead drug, onvansertib, and upcoming detailed Phase 2 data at ASCO.


Key Events · Earnings and Guidance · CRDF

  • Q1 2026 Financial Results

    The company reported approximately $46.1 million in cash, cash equivalents, and short-term investments as of March 31, 2026.

  • Short Cash Runway

    Current cash resources are projected to fund operations only into the first quarter of 2027, indicating a critical need for additional financing.

  • FDA Alignment for Phase 3 Trial

    Cardiff Oncology completed a successful End-of-Phase 2 meeting with the FDA, aligning on the 30 mg dose of onvansertib with FOLFIRI/bev chemotherapy for the planned Phase 3 trial in first-line RAS-mutated metastatic colorectal cancer.

  • Upcoming ASCO Presentation

    The company will present detailed updated data from its randomized Phase 2 CRDF-004 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2.


Analysis · CRDF · Life Sciences

Cardiff Oncology reported Q1 2026 financial results, revealing approximately $46.1 million in cash and a cash runway projected only into the first quarter of 2027. This short runway, coupled with the 'going concern' warning in the concurrent 10-Q, highlights significant financial challenges and an urgent need for additional financing. Despite this, the company announced positive clinical progress, including a successful End-of-Phase 2 meeting with the FDA, aligning on the design and dose for a pivotal Phase 3 trial for its lead asset, onvansertib. Further detailed Phase 2 data will be presented at the upcoming ASCO Annual Meeting. The market will weigh the positive clinical momentum against the critical need for capital to fund the planned Phase 3 trial.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRDF was trading at $1.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $118.3M. The 52-week trading range was $1.48 to $4.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRDF - Latest Insights

CRDF
Nov 16, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8328
Real-time Price: $0.8358 info
Change: +$0.0030 (+0.36%) info
Market Cap: $66.344M info
CRDF
Nov 12, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7276
Real-time Price: $0.8358 info
Change: +$0.1082 (+15%) info
Market Cap: $66.344M info
CRDF
Nov 12, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7276
Real-time Price: $0.8358 info
Change: +$0.1082 (+15%) info
Market Cap: $66.344M info
CRDF
Nov 12, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7695
Real-time Price: $0.8358 info
Change: +$0.0663 (+9%) info
Market Cap: $66.344M info
CRDF
Oct 27, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8988
Real-time Price: $0.8358 info
Change: -$0.063 (-7%) info
Market Cap: $66.344M info